## Chantana Polprasert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/932869/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies. Hematology, 2022, 27, 181-186.	0.7	2
2	Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry. Hematology Reports, 2022, 14, 13-18.	0.3	0
3	Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e915-e921.	0.2	2
4	Genetic mutations associated with blood count abnormalities in myeloid neoplasms. Hematology, 2022, 27, 765-771.	0.7	2
5	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leukemia and Lymphoma, 2021, 62, 95-103.	0.6	12
6	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	5.1	46
7	Daratumumab rapidly reduces highâ€ŧitre factor VIII inhibitors in haemophilia A patients during lifeâ€ŧhreatening haemorrhages. Haemophilia, 2021, 27, e155-e159.	1.0	5
8	Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e635-e643.	0.2	3
9	EXCELLENT PROGNOSIS OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DETECTABLE MYELOID-RELATED MUTATIONS. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
10	Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy. Blood Research, 2021, , .	0.5	0
11	Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes. Asian Pacific Journal of Cancer Prevention, 2021, 22, 4037-4042.	0.5	0
12	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. Acta Haematologica, 2020, 143, 78-88.	0.7	21
13	Novel DDX41 variants in Thai patients with myeloid neoplasms. International Journal of Hematology, 2020, 111, 241-246.	0.7	20
14	Comprehensive screening for coexisting heterozygous α0-thalassemia in hemoglobin E trait. Hematology, 2020, 25, 276-279.	0.7	0
15	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
16	Cold agglutinin disease following SARSâ€CoVâ€2 and <i>Mycoplasma pneumoniae</i> coâ€infections. Clinical Case Reports (discontinued), 2020, 8, 2402-2405.	0.2	8
17	Clinical Impacts of Germline <i>DDX41</i> Mutations on Myeloid Neoplasms. Blood, 2020, 136, 38-40.	0.6	7
18	Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia – A multicenter prospective registry in Thai population. Leukemia Research, 2019, 87, 106235.	0.4	2

CHANTANA POLPRASERT

#	Article	IF	CITATIONS
19	Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients Hematology Reports, 2019, 11, 8183.	0.3	10
20	Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Advances, 2019, 3, 588-595.	2.5	73
21	Genetic Mutation in Cytopenic Patients: Distinctive Genomic Profile between Preclinical Vs. Clinical Myelodysplastic Syndrome. Blood, 2019, 134, 5429-5429.	0.6	0
22	A Randomized Multicenter Trial Comparing Low-Dose Prednisolone Versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 867-873.	0.7	8
23	Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e509-e514.	0.2	6
24	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	7.7	341
25	Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53. Blood, 2014, 124, 784-784.	0.6	0
26	Case report: severe CMV colitis in a patient with follicular lymphoma after chemotherapy. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2011, 94, 498-500.	0.4	8